How Silence Therapeutics (SLN) Is Building the Divesiran Case Around Fewer Blood Draws in Polycythemia Vera

Silence Therapeutics plc (NASDAQ:SLN) is one of the small-cap stocks with potential to rise 1000 percent. The company’s lead story is divesiran, an experimental treatment for polycythemia vera, a rare blood cancer in which the body makes too many red blood cells. Patients often need repeated blood draws to lower red blood cell levels, and Silence is trying to reduce that treatment burden with a drug designed to turn down a disease-related gene signal.

On June 11, Silence presented follow-up Phase 1 data from the SANRECO study at the European Hematology Association 2026 Congress. In the six months before treatment, 21 patients needed 80 blood draws. During active treatment, that number fell to 5, and only 4 more blood draws were reported during the 16-week follow-up period after the final dose. Among 14 patients with longer follow-up, the median time to the first blood draw was 287 days.

Monika Wisniewska/Shutterstock.com

The next test is larger. Silence said its Phase 2 SANRECO study remains on track for top-line results in August 2026. The company ended the first quarter with $70.1 million in cash, cash equivalents, and short-term investments.

Silence Therapeutics plc (NASDAQ:SLN) is a clinical-stage biotechnology company developing RNA-based medicines for blood disorders, cardiovascular disease, and rare diseases.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.